We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Julian
Knight
julian@well.ox.ac.uk
Dr
Julian
Knight
julian@well.ox.ac.uk
Dr
Julian
Knight
julian@well.ox.ac.uk
Other bacterial diseases
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This study aims to understand the molecular pathophysiology of sepsis in order to improve patient care. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Currently we do not understand why only a minority of patients develop this extreme response to infection, why there is variability in the sepsis response and how best to identify specific sepsis patients who will benefit from particular treatments. This is important as in the UK, sepsis is a major public health burden, responsible for 1 in 20 deaths in England with few effective treatments. Mortality remains higher than 25-30% and up to 40-50% in severe cases. Nearly a third of UK ICU admissions are for patients with sepsis, where it is the most common cause of death.
To better understand sepsis biology and the individual sepsis response, we propose to recruit up to 1100 adult patients admitted to UK hospitals (including 300 control patients), especially intensive care units, for a prospective non-interventional observational study. Samples will include blood, urine, faeces, respiratory specimens. We will apply the most current immunological and functional genomic technologies to understand the nature of the sepsis response and its variability.
The study will initially be run at the John Radcliffe Hospital in Oxford, but other centres will then be included to increase patient recruitment with the study to run over 5 years. Processing of biological material will primarily be done at the Wellcome Centre for Human Genetics and Weatherall Institute of Molecular Medicine in Oxford.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Exclusion criteria: Patients < 18 years of age Patient, personal or nominated consultee unwilling or unable to give written informed consent / advice Pregnancy and up to 6 weeks post partum Advanced directive to withhold or withdraw life-sustaining treatment Admission for palliative care only Severe acquired immunodeficiency e.g. - high dose steroid therapy (prednisolone or equivalent 0.5mg/kg/day for 14 days or longer (inhaled, intra-articular or topical steroids not considered)) - HIV infection - known regular therapy with other immunosuppressive agents (e.g. azathioprine) - neutrophil count less than 1000 mm-3 due to any cause including metastatic disease and haematological malignancies or chemotherapy, but excluding severe sepsis - an organ or bone marrow transplant receiving immuno-suppressive therapy Control patients: - exclusion criteria same as for sepsis patients
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Julian
Knight
julian@well.ox.ac.uk
Dr
Julian
Knight
julian@well.ox.ac.uk
Dr
Julian
Knight
julian@well.ox.ac.uk
The study is sponsored by University of Oxford and funded by Wellcome Trust .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 42294
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
